• 1. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 2. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 5. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Linear 1,3-diarylpropanoids Retro-dihydrochalcones
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Linear 1,3-diarylpropanoids Chalcones and dihydrochalcones Retro-dihydrochalcones

Recent Advances in Loureirin C (116384-24-8) Research: A Comprehensive Review

Loureirin C (CAS: 116384-24-8), a bioactive flavonoid derived from the traditional Chinese herb Dracaena cochinchinensis, has garnered significant attention in recent years due to its promising pharmacological properties. This research briefing synthesizes the latest findings on Loureirin C, focusing on its chemical characteristics, biological activities, and potential therapeutic applications. The compound's unique structure and multifaceted mechanisms of action make it a compelling subject for ongoing research in the field of chemical biology and pharmaceutical sciences.

Recent studies have elucidated the molecular structure of Loureirin C, revealing its potential as a modulator of various signaling pathways. A 2023 study published in the Journal of Natural Products demonstrated its ability to interact with key inflammatory mediators, suggesting potential applications in treating chronic inflammatory diseases. The compound's specificity and low toxicity profile, as evidenced by in vitro and in vivo studies, position it as a promising candidate for further drug development.

In the realm of oncology research, Loureirin C has shown remarkable potential. A groundbreaking 2024 study in Cancer Research reported its ability to inhibit tumor growth in xenograft models through modulation of the PI3K/AKT/mTOR pathway. The study highlighted the compound's dual functionality as both a cytotoxic agent and a sensitizer for conventional chemotherapy, opening new avenues for combination therapies in resistant cancer types.

Pharmacokinetic studies of Loureirin C have made significant progress in the past year. Advanced analytical techniques, including UPLC-Q-TOF-MS/MS, have enabled researchers to track the compound's metabolism and distribution patterns with unprecedented precision. These findings, published in the European Journal of Pharmaceutical Sciences, provide crucial insights for formulation development and dosage optimization in future clinical applications.

The neuroprotective effects of Loureirin C have emerged as another exciting research frontier. Recent work in Neuropharmacology demonstrated its ability to cross the blood-brain barrier and exert protective effects against oxidative stress in neuronal cells. These findings suggest potential applications in neurodegenerative disorders, though further validation in animal models is required to substantiate these preliminary observations.

From a chemical synthesis perspective, novel methodologies for Loureirin C production have been developed to address supply limitations. A 2023 paper in Organic Letters described an efficient semi-synthetic route with improved yield and purity, overcoming previous challenges in large-scale production. This advancement is particularly significant for facilitating future preclinical and clinical studies.

Despite these promising developments, challenges remain in translating Loureirin C research into clinical applications. Current limitations include incomplete understanding of its off-target effects and potential drug-drug interactions. Ongoing research efforts are focusing on structure-activity relationship studies to optimize its pharmacological profile while minimizing adverse effects.

In conclusion, Loureirin C (116384-24-8) represents a compelling case study in natural product drug discovery. The convergence of recent findings across multiple disciplines - from structural biology to pharmacology - underscores its therapeutic potential. As research continues to unravel its complex mechanisms of action, Loureirin C stands poised to make significant contributions to the development of novel treatments for various diseases, pending successful translation of these discoveries into clinical practice.

• 80370-27-0(1,3-Propanedione, 1-(2,4-dimethoxyphenyl)-3-(4-methoxyphenyl)-)
• 76288-41-0(1,3-Propanedione,1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-methoxyphenyl)-)
• 64231-05-6(1,3-Pentanedione, 1-(2,4,6-trimethoxyphenyl)-)
• 65547-54-8(1-(2,4-dimethoxyphenyl)butane-1,3-dione)
• 119425-91-1(Loureirin D)
• 119425-89-7(Loureirin A)
• 119425-90-0(Loureirin B)
• 19103-52-7(1-Propanone, 3-(2-hydroxy-4,6-dimethoxyphenyl)-1-(4-methoxyphenyl)-)
• 76569-40-9(PHLOROBUTYROPHENONE TRIMETHYL ETHER)
• 519-40-4(1-(2,6-dihydroxy-4-methoxy-3-methylphenyl)butan-1-one)